An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
- A Gentler Cell Line Selection Method Using microRNA
- Controls For Retrieval-Augmented Generation In GxP
- Implementing AI Solutions In GMP While Managing Risk
- Implementing And Optimizing Your eQMS
- A Much-Improved Approach For Understanding And Managing Safety Risks
- CSV Assumes The AI System Sits Still — It Doesn't.
- July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing
GUEST COLUMNISTS
-
A Gentler Cell Line Selection Method Using microRNA
Traditional selection stresses surviving cells. New research shows how structurally interacting RNA may use endogenous microRNA for a faster, nontoxic selection process.
-
Controls For Retrieval-Augmented Generation In GxP
Validation teams deal with inherent variability all the time. The same principles for GMP — think visual inspection — can apply to probabilistic AI systems.
-
Implementing AI Solutions In GMP While Managing Risk
When using artificial intelligence in GMP settings, risk management extends far beyond validation. This discussion explores moving AI solutions out of the pilot phase.
-
Implementing And Optimizing Your eQMS
This article addresses everything that follows the signed contract for an eQMS: how a system is configured, validated, adopted, and maintained.
-
A Much-Improved Approach For Understanding And Managing Safety Risks
Learn how causal mechanism and effect analysis (CMEA) and its principles can be used to develop and maintain safer working environments in the pharma/biotech and medical device industries.
-
CSV Assumes The AI System Sits Still — It Doesn't.
The computer system validation playbook was written for software that holds its shape. AI doesn't. Validating it has to become an act of governance.
-
July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing
Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.
BIOSIMILAR WHITE PAPERS
-
Aseptic Process Design And Simulation Under Annex 1 Guidelines
Gain insight into how Annex 1 reshapes aseptic process validation, as well as into risk reduction by design and why isolators are redefining modern sterile manufacturing standards.
-
Performance Characteristics Of The Mobius® ADC Reactor For Conjugation10/22/2024
Explore results from a series of studies evaluating the mixing performance of an innovative ADC reactor during the conjugation step utilizing a model fluid.
-
A Comprehensive Solution For Adventitious Agent Testing2/13/2026
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
-
Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer3/24/2025
Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency and innovation in bioprocessing workflows.
-
A Risk-Based Approach To Plasmid DNA And mRNA Process Development9/23/2025
Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
-
Is Sustainability The Key To Agile Biopharma Manufacturing?3/18/2025
In biologics manufacturing, change is constant. Discover how new innovations and a focus on sustainability have gotten 62% of executives to prioritize eco-friendly practices, which reflects a commitment to long-term viability.
BIOSIMILAR APP NOTES & CASE STUDIES
- Extractables In Single-Use Systems Used In ADC Manufacturing
- Developing CAR T Therapies With A Cell Therapy Manufacturing Platform
- Comparing Process Development Approaches For Recombinant Proteins
- Implementation Of Multi-Column Chromatography Systems
- Process Intensification Through Downstream Connectivity
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Indian Pharmacopoeia Commission (IPC) Organizes National Conference On Quality And Safety Of Biosimilars: Strengthening India's Biopharma SHAKTI Vision
- U.S. Generic & Biosimilar Medicines Save $496B In Just 1 Year
- Henlius Open Day 2026: Systematic Global Expansion Drives C-MNC Vision, Innovation Fuels New Peaks
- Sandoz Invests In New Drug Substance Facility In Ljubljana, Slovenia, To Expand Biosimilar Manufacturing Capacity
- Samsung Bioepis Gains Marketing Approval In Japan For 130mg Intravenous Infusion Of Ustekinumab Biosimilar
- Cipla Announces Exclusive Partnership With Qilu Pharmaceutical For The Licensing And Supply Of Biosimilar To Keytruda® (Pembrolizumab) In The US
- Alvotech Announces FDA Acceptance For Review Of Biologics License Application For AVT80, Expanding Proposed Biosimilar Program For Entyvio® To Subcutaneous Presentations
- Samsung Bioepis Initiates Phase 1 Clinical Trial For SB35, A Biosimilar Candidate Referencing Taltz (Ixekizumab)
NEWSLETTER ARCHIVE
- 09.16.26 -- Smarter Ways To Reduce Risk, Downtime, And Lifecycle Surprises
- 09.10.26 -- U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing
- 09.03.26 -- Why Trusted Data Is A Process Variable in Bioprocessing
- 08.27.26 -- The Missing Piece In Biosimilar Adoption
- 08.20.26 -- Exploring Takeda's Template For Sustainable Steam Generation